Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

Lupus

Volumn 16, Issue 1, 2007, Pages 39-45

  Tarr, T ^a   Lakos, G ^a   Bhattoa, H P ^a   Shoenfeld, Y ^b   Szegedi, G ^a   Kiss, Emese ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b TEL AVIV UNIVERSITY   (Israel)

^c Department of Clinical Immunology ^*  (Hungary)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Primary prophylaxis; SLE; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; COUMARIN; FIBRINOLYTIC AGENT; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 33846616931     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306074767     Document Type: Article

References (42)

1. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983; 287: 1088-1089.
2. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.
3. Asherson RA, Cervera R. 'Primary', 'secondary' and other variants of the antiphospholipid syndrome. Lupus 1994; 3: 293-298.
4. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1743.
5. Louizu S, Mackworth-Young CG, Cofiner C, Walpoprt MJ. Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis. Clin Exp Immunol 1990; 80: 171-176.
6. Viard JP, Amoura Z, Bach JF. Association of anti-beta2-gylcoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186.
7. Sheonfeld Y, Meroni PL. The beta-2-glycoprotein I and antiphospholipid antibodies. Clin Exp Rheumatol 1992; 10: 205-209.
8. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta-2-gylcoprotein I structure altered by intercating with oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462.
9. Lakos G, Kiss E, Regeczy N et al. Anti-prothrombin and anti-annexin V antibodies imply a risk of thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2000; 27: 924-929.
10. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody mediated atherosclerosis. Autoimmun Rev 2002; 1: 348-353.
11. Gharavi AE, Wilson W, Pierangeli S. The molecular basis of antiphospholipid syndrome. Lupus 2003; 12: 579-583.
12. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999; 25: 333-350.
13. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-2536.
14. De Bandt M, Benali K, Guillevin L et al. Longitudinal determination of antiphospholipid antibodies lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol 1999; 26: 91-96.
15. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003; 12: 302-307.
16. Urfer C, Pichler WJ, Halbling A. Antiphospholipid antibodies syndrome: follow-up of patients with a high antiphospholipid antibody titer. Schweitz Med Wochenschr 1996; 126: 2136-2140.
17. McClain MT, Arbuckle MR, Heilen LD et al. The prevalence, onset and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthitis Rheum 2004; 50: 1226-1232.
18. Gomez-Puerta JA, Martin H, Amigo MC et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84: 225-230.
19. Petri M. Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. Curr Rheumatol Rep 2003; 5: 370-373.
20. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
21. Derksen RH, De Groot PG, Rappelle LJ. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology 2003; 61: 111-114.
22. Ruiz-Irastorza G, Khamashta MA, Hughes GR. Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmunity Rev 2002; 1: 298-304.
23. Khamashta MA, Shoenfeld Y. Antiphospholipid syndrome: a consensus for treatment? Lupus 2003; 12: 495.
24. Alargon-Segovia D, Boffa MC, Branch W et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003; 12: 499-503.
25. Miyakis S, Lockshin MD, Astumi T et al. International consensus statement on an update of the classification criteria dor definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
26. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-222.
27. Lakos G, Kiss E, Regeczy N et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (β2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999; 117: 574-579.
28. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for the testing and revised criteria for lupus anticoagulant. Thromb Haemost 1991; 65: 320-322.
29. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-992.
30. Cervera R, Piette JC, Font J et al. for the Euro-Phospholipid Project Group. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
31. Danowski A, Kickler TS, Petri M. Anti-β2-glycoprotein I: Prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus ertyhematosus. J Rheumatol 2006; 33: 1775-1779.
32. Mari I, Gilburd B, Blank M, Shoenfeld Y. Anti-cariolipin and anti-β2-glycoprotein I (β2GP-I) antibody assays as screening for anti-phospholipid syndrome, Human Antibodies 2003; 12: 57-62.
33. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GRV. Systemic lupus erythematosus. Lancet 2001; 357: 1027-1032.
34. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998; 7: 3-6.
35. Meroni PL, Moia M, Derksen RH et al. Venous thromboembolism in the antiphospholipid syndrome management guidelines for secondary prophylaxis. Lupus 2003; 12: 504-507.
36. Brey RL, Chapman J, Leine SR et al. Stroke and the antiphospho-lipid syndrome: consensus meet Taormina 2002. Lupus 2003; 12: 508-513.
37. Lockshin MD, Erkan D. Treatment of antiphospholipid syndrome. N Engl J Med 2003; 349: 1177-1179.
38. Asherson RA, Cervera R. The antiphospholipid syndrome: multiple faces beyond the classical presentation. Autoimm Rev 2003; 2: 140-151.
39. Tincani A, Branch W, Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-529.
40. Lockshin M, Tenedios F, Petri M et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003; 12: 518-523.
41. Galli M, Barbui T. Antiphospholipid antibodies and thrombosis: strength of association. Hematol J 2003; 4: 180-186.
42. Zandman-Goddard G, Blank M, Sherer Y et al. 10th International congress on antiphospholipid antibodies - summary. Autoimm Rev 2003; 2: 79-85.